Aurobindo Pharma Q1 FY27 profit up 25%, revenue record

Profit and revenue beat expectations

Aurobindo Pharma reported a strong June-quarter performance (Q1FY27), with consolidated profit and revenue rising at a double-digit pace. Consolidated net profit increased 25.2% year-on-year to ₹1,032 crore, compared with ₹824 crore in Q1FY26. Revenue from operations rose 16.3% year-on-year to a record ₹9,150 crore. A CNBC-TV18 poll referenced in the report had pegged profit at ₹982 crore and revenue at ₹9,030 crore, which the company exceeded. The earnings were attributed in the report to growth across key markets, improved operating performance and new product launches in the US. The company’s results also “beat CNBC-TV18 poll estimates” on operating profit, according to the same coverage. The reported numbers place the quarter among the stronger recent prints for the Hyderabad-based drugmaker.

How operating performance moved this quarter

On operating metrics, the reported data includes more than one EBITDA presentation used by different sources. Operating EBITDA, excluding forex impact and other income, rose 20% year-on-year to ₹1,924 crore, with the EBITDA margin expanding by 60 basis points to 21%. Another set of figures cited in the same information stream put EBITDA (excluding other income) at ₹1,881 crore versus ₹1,603 crore in Q1FY26, a 17.34% year-on-year increase. Under that presentation, EBITDA margin stood at 20.56% in Q1FY27 versus 20.37% in Q1FY26 and 19.80% in Q4FY26. The company was also described as marginally exceeding a “Street estimate” of 20.5% margin. Taken together, the data points to margin stability to improvement, alongside growth in revenue.

Key quarter-on-quarter trend points

Beyond year-on-year changes, the company also showed sequential improvement from Q4FY26 on several lines. Revenue from operations rose to ₹9,150 crore from ₹8,853 crore in Q4FY26, a 3.35% quarter-on-quarter increase. Profit after tax increased to ₹1,032 crore from ₹921 crore in Q4FY26, up 12.07% QoQ. EBITDA (excluding other income) increased to ₹1,881 crore from ₹1,753 crore in Q4FY26, a 7.32% QoQ rise. EBITDA margin improved to 20.56% from 19.80% in the previous quarter, an expansion of 0.76 percentage points. PAT margin improved to 11.28% from 10.40% in Q4FY26. These sequential changes, as provided in the figures, indicate improving profitability even as revenue advanced.

Market-wise revenue: US, Europe and growth markets

The report also broke out performance by key geographies and business lines. Revenue from the US market grew 8.1% year-on-year to ₹3,770 crore. Europe revenue rose 25.6% year-on-year to ₹2,937 crore. Growth Markets revenue increased 37.7% year-on-year to ₹1,063 crore. The ARV business was reported at ₹330 crore for the quarter. The combination of moderate US growth and sharper growth in Europe and Growth Markets supported the overall double-digit top-line expansion reflected in the quarter.

Segment update: formulations and API

At the segment level, formulations remained the larger contributor in the quarter. The formulations segment recorded year-on-year growth of 16.5% to ₹8,101 crore. API revenue increased 14.6% year-on-year to ₹1,049 crore. These segment figures align with the broader revenue-from-operations line reported for the quarter. They also indicate that growth was not concentrated in a single division, with both formulations and API expanding year-on-year.

Regulatory and product pipeline: USFDA approvals and ANDAs

On the US pipeline, Aurobindo Pharma secured final approval from the USFDA for 10 products during the quarter, as stated in the report. The same information also noted that the company had submitted 896 ANDAs to the USFDA as of June 30, and had received 33 final approvals. These disclosures are relevant for investors tracking the sustainability of US revenues and the pace of product additions. The company’s quarter commentary in the report linked performance to new product launches in the US. The approvals and filings data provides a reference point for that narrative.

Balance sheet and cash flow actions cited

The report highlighted corporate actions and cash generation in dollar terms. It stated that Aurobindo completed a USD 247 million acquisition of Lannett and also executed a USD 85 million share buyback. It also reported free cash flow generation of USD 98 million during the quarter. These items were presented as completed actions and a quarterly cash flow figure, respectively. Separately, profit before tax was reported to have increased 25.9% to ₹1,517 crore. Earnings per share were reported at ₹17.86.

Stock move and how the Street tracked estimates

Ahead of the earnings announcement, Aurobindo Pharma shares ended Wednesday’s session 1.83% higher at ₹1,615 on the NSE, according to the report. In addition to the beat versus the CNBC-TV18 poll on profit and revenue, EBITDA was also cited as above estimate. The poll estimate referenced EBITDA at ₹1,848 crore, compared with the reported ₹1,881 crore figure under the “excluding other income” presentation. Operating margin was cited at 21% in the CNBC-TV18 comparison, improving from 20% a year ago, and also described as marginally above a 20.5% Street estimate. The mix of beats and margin improvement is what typically shapes the immediate market narrative around quarterly results.

Key numbers snapshot (as reported)

Why the quarter matters for investors

The quarter stands out for two clear data points in the report: record revenue from operations of ₹9,150 crore and a 25.2% year-on-year rise in profit to ₹1,032 crore. Market-wise numbers showed Europe and Growth Markets growing faster than the US, while the US still remained a large contributor at ₹3,770 crore. From a profitability lens, margins were reported as improving to around 21% on an operating basis, alongside a PAT margin of 11.28% in the detailed quarterly table. Regulatory updates, including 10 USFDA final approvals in the quarter and the cumulative ANDA filing and approval counts disclosed, add context on the product pipeline that underpins US business momentum. Corporate actions and cash flow figures cited, including the Lannett acquisition and buyback, provide additional context on capital allocation alongside earnings.

Conclusion

Aurobindo Pharma’s Q1FY27 results showed stronger profitability on double-digit revenue growth, with reported beats versus poll estimates on key lines. The company also disclosed USFDA approvals and broader filing and approval counts, alongside cash flow generation and recent corporate actions. Investors will track whether the growth seen in Europe and Growth Markets sustains, and how the product flow in the US shapes upcoming quarters based on the approvals and launches referenced in the report.